Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron phase 2 stem cell trials still on track

UK based clinical stage stem cell business, ReNeuron is moving ahead with its programme of clinical trials. The CFO, Michael Hunt, tells Proactiveinvestors the company is expecting initial results from its phase 2 trials of CTX for stroke victims by the end of 2015 with further data from that trial in the early part of 2016.

The company is also expecting the CLI programme to move out of phase I and into phase II in the second half of this year, and the phase I/II retinitis pigmentosa trial is expected to commence in the US this year.

ReNeuron raised £25 million in 2013 and has the funding in place to complete all of these clinical trials. It is also opening a world class cell manufacturing facility in South Wales.

 
Meet Core Exploration Ltd, Arrow Minerals Ltd, PNX Metals Ltd and King River Copper Ltd at our event, Melbourne , 25 June 2018. Register here »
View full RENE profile View Profile

ReNeuron Group Plc Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use